Skip to content
Levobunolol
Betagan (levobunolol) is a small molecule pharmaceutical. Levobunolol was first approved as Betagan on 1985-12-19. It is used to treat open-angle glaucoma in the USA. The pharmaceutical is active against beta-3 adrenergic receptor, beta-1 adrenergic receptor, and beta-2 adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Betagan (generic drugs available since 1994-03-04, discontinued: Akbeta)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levobunolol hydrochloride
Tradename
Company
Number
Date
Products
BETAGANAllerganN-019219 RX1985-12-19
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
levobunolol hydrochlorideANDA2016-08-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
open-angle glaucomaEFO_0004190D005902H40.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01ED: Beta blocking agents, antiglaucoma preparations and miotics
— S01ED03: Levobunolol
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ocular hypertensionD009798EFO_1001069H40.0——2——2
GlaucomaD005901EFO_0000516H40——1——1
Open-angle glaucomaD005902EFO_0004190H40.1——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLEVOBUNOLOL
INNlevobunolol
Description
Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrenergic antagonist. It is a propanolamine, a cyclic ketone and an aromatic ether. It is a conjugate acid of a levobunolol(1+). It derives from a hydride of a tetralin.
Classification
Small molecule
Drug classbeta-blockers (propranolol type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O
Identifiers
PDB—
CAS-ID47141-42-4
RxCUI1813
ChEMBL IDCHEMBL1201237
ChEBI ID6438
PubChem CID39468
DrugBankDB01210
UNII IDG6317AOI7K (ChemIDplus, GSRS)
Target
Agency Approved
ADRB3
ADRB3
ADRB1
ADRB1
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB3
Gene synonyms
ADRB3R, B3AR
NCBI Gene ID
155
Protein name
beta-3 adrenergic receptor
Protein synonyms
adrenergic, beta-3-, receptor, Beta-3 adrenoceptor, Beta-3 adrenoreceptor
Uniprot ID
Q4JFT4
Mouse ortholog
Adrb3 (11556)
beta-3 adrenergic receptor (Q9QZ98)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 427 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details